Prime Medicine, Inc. Lease, Cost
Prime Medicine, Inc. (PRME) reported Lease, Cost of $33.99 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-03
- Prime Medicine, Inc. lease, cost for fiscal 2025 was $33.99M, a 40.27% increase from fiscal 2024.
- Prime Medicine, Inc. lease, cost for fiscal 2024 was $24.23M, a 31.31% increase from fiscal 2023.
- Prime Medicine, Inc. lease, cost for fiscal 2023 was $18.46M, a 39.65% increase from fiscal 2022.
- Prime Medicine, Inc. lease, cost for fiscal 2022 was $13.22M, a 158.60% increase from fiscal 2021.
| Period end | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|
| 2025-12-31 | $33.99M 10-K · filed 2026-03-03 | |
| 2024-12-31 | $24.23M 10-K · filed 2026-03-03 | |
| 2023-12-31 | $18.46M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $13.22M 10-K · filed 2024-03-01 | $13.51M 10-K · filed 2023-03-09 |
| 2021-12-31 | $5.11M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |